Pure Global
NCT06122142

Spatial Repellents for Malaria Control

Advancing Spatial Repellents for Malaria Control: Effectiveness and Cost-Effectiveness of a Spatial Repellent Under Operational Use in Northern Uganda
University of Notre Dame·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Transfluthrin - delivery by paid study personnel
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University of Notre Dame
Location
Kampala,Kampala, Uganda
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Jan 01, 2025
Enrollment
2160 participants
Primary outcome

Effectiveness of SR against malaria infection (both first-time and recurrent).

Summary

The primary objective of the study is to demonstrate and quantify the effectiveness of a
 spatial repellent (SR) product, in reducing malaria infection in humans under operational
 program conditions in a humanitarian assistance context. The design will be a cluster
 Randomized Control Trial (cRCT) representing an operational research study.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06122142
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06122142 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Notre Dame and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 2160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.